RxDoctor Payments Data

Chris Hyun, MD

Gastroenterology · Tigard, ORNPI 1447230594

Payments from drug & device makers

$981in general payments, 2019–2025

Across 37 payments — averaging $26.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$133
  • Gilead$125
  • Nestle Healthcare Nutrition Inc.$113
  • Aimmune Therapeutics, Inc.$109
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$89
  • Intercept Pharmaceuticals, Inc.$71
  • plus $340 from 10 others

What the payments were for

  • Food & beverage$90292%
  • Education$788%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$981 in reported general payments places this provider in the 65th percentile of 220 gastroenterology providers in Oregon.

See all gastroenterology providers in Oregon

Medicare billing

Part B allowed, 2024
$38,050
Medicare patients
163
Services billed
843

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase17$92,275
CreonLipase/Protease/Amylase18$52,408
Mesalamine45$23,152
Mesalamine ErMesalamine22$16,565
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates170$10,306
Omeprazole303$6,198
Ursodiol19$3,683
SuprepSodium, Potassium,mag Sulfates26$2,800
Balsalazide Disodium12$2,544
SutabSod Sulf/Pot Chloride/Mag Sulf14$2,330
Tenofovir Disoproxil Fumarate13$2,251
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag16$2,030
Mercaptopurine15$1,981
Mesalamine DrMesalamine11$1,065
Pantoprazole Sodium86$1,055

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aimmune Therapeutics, Inc.Zenpep$109$92,27517 claims
AbbVieCreon$133$52,40818 claims
Braintree Laboratories, Inc.Sutab, Suflave$14$4,36030 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 220 gastroenterology providers in Oregon.

Other gastroenterology in Tigard

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →